Reviva Pharmaceuticals Holdings, Inc. (RVPH), a late-stage biopharmaceutical company, priced its previously announced public offering for the sale of 6.66 million shares, together with series G warrants to purchase up to 6.66 million shares and series H warrants to purchase up to 6.66 million shares at a combined offering price of $1.50 per share.
The gross proceeds are expected to be approximately $10 million, and the offering is expected to close on or about March 20, 2026.
Following the news, RVPH is down 33.16% at $1.25 in the overnight market.
The company intends to use the net proceeds from the offering to fund research and development activities, including its planned RECOVER-2 Phase 3 trial for Brilaroxazine in Schizophrenia, and for working capital and other general corporate purposes.
The series G warrants and the series H warrants will have an exercise price of $1.50 per share.
The series G warrants will be exercisable immediately and will expire five years from the issuance date, while the series H warrants will be exercisable immediately and will expire 12 months from the issuance date.
A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
Reviva's current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases and includes two drug candidates, Brilaroxazine (RP5063) and RP1208.
RVPH has traded between $1.82 and $23.4 in the last year. The stock closed Wednesday's trade at $1.87, down 19.40%.
For More Such Biotech and Pharmaceutical News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.